Abstract
Pulmonary artery hypertension (PAH) is common cardio-pulmonary phenomenon associated with higher risk of premature death and disability. Several previous studies have shown that decreased number of circulating endothelial progenitor cells (EPCs) correlated well with vascular remodeling and impaired pulmonary artery function. Moreover, a deep deficiency of EPC characterized a poor clinical outcomes in PAH individuals. There is large body of evidence regarding that the EPCs could be not just biomarker of endothelial dysfunction, but a target of PAH therapy. However, improvement of PAH severity associated with increasing number of circulating EPC with angiopoetic phenotype accompanying sildenafil care. The short communication is depicted the predictive role of EPCs in risk stratification in PAH patients and possibilities to use EPC-based care aimed improving clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
